Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NRX Pharmaceuticals, Inc. - Common Stock (NQ:NRXP)

2.355 -0.055 (-2.28%)
Streaming Delayed Price Updated: 12:52 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 578,485
Open 2.350
Bid (Size) 2.350 (5,000)
Ask (Size) 2.360 (1,100)
Prev. Close 2.410
Today's Range 2.317 - 2.430
52wk Range 1.580 - 3.840
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-10.1%
-10.1%
1 Month
+33.8%
+33.8%
3 Month
-3.5%
-3.5%
6 Month
-21.2%
-21.2%
1 Year
+17.2%
+17.2%

More News

Read More
News headline image
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
Via ACCESS Newswire
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules March 24 Conference Call To Review 2025 Results And Clinical Progress
Via Investor Brand Network
News headline image
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Guidance Supporting NDA Review For NRX-100
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
New to The Street Episode #737 Airs on Bloomberg Television Across the United States, Latin America, and MENA at 6:30 PM EST
Via ACCESS Newswire
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer
Via Investor Brand Network
News headline image
Effective One Day Treatment for Depression and PTSD Now Available at New Florida Clinic: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Depression and PTSD Treatment
Via Investor Brand Network
News headline image
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
New to The Street Broadcasts Tonight on Bloomberg Television at 6:30 PM EST - Shows 736, 737 and 738 Air Across the U.S., Latin America and MENA
Via ACCESS Newswire
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Builds Momentum From FDA Progress To Strategic Expansion
Via NewMediaWire
News headline image
NRx Builds Momentum From FDA Progress To Strategic Expansion
Via TheNewswire.com
News headline image
FDA Meeting Indicates Path to New Drug Application with Real World Data and Broader Indication of NRX-100 (Ketamine) for Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway
Via Investor Brand Network
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
From NRx Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Milestone Patient Data Eclipsing 70,000 on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Via Get News
PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100
Via Investor Brand Network

Frequently Asked Questions

Is NRX Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, NRX Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does NRX Pharmaceuticals, Inc. - Common Stock trade on?
NRX Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for NRX Pharmaceuticals, Inc. - Common Stock is NRXP on the Nasdaq Stock Market
What is the current price of NRX Pharmaceuticals, Inc. - Common Stock?
The current price of NRX Pharmaceuticals, Inc. - Common Stock is 2.355
When was NRX Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of NRX Pharmaceuticals, Inc. - Common Stock was at 03/26/26 12:52 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.